Navigation Links
NCX in Medical Technology

NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan

SOPHIA ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. A preliminary analysis of 11 patients from this proof-of-concept study in...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

...se 2 proof-of-concept study for TPI 1020 (formerly ncx 1020) in Chronic Obstructive Pulmonary Disease (CO...ca and an option to obtain rest of world rights. ncx 4016 ncx 4016 is a nitric oxide-donating derivative of acet...

NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology

... focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx' Naproxcinod ABPM Data Presented at American Heart Association

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

...res, Argentina. These included phase 1 results for ncx 1022, a prototype compound, showing the potential ...edical services. Furthermore, the clinical data on ncx 1022 suggest that nitric oxide donation may also i...owing encouraging results from a phase 1 study for ncx 1022, a lower potency prototype (see top-line resu...

NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...
NCX in Biological News

Biophysical Society announces 2008 International Travel Awards

...omputational Model of Ventricular Tissue. Carlo Manno, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela, Importance of ncx in the Regulation of Ca2+ Homeostasis in Skeletal Muscle. Maria V. Mernea, University of Bucharest, Romania, A Three-Dimensional Model of Epit...
NCX in Biological Technology

NicOx to Present at Financial Conferences in New York on November 27, 28 and 29

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...

NicOx Opens U.S. Headquarters in New Jersey

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...
Other Tags
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... eight hundred births, Down syndrome - or trisomy 21 ... disability. It results from a chromosomal abnormality where cells ... 21 (1% of the human genome). A study conducted ... of Genetic Medicine and Development at the University of ... , shed light on how the extra chromosome 21 ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
Other Contents